# Apatinib Combined With Chemotherapy for NSCLC Patients Without T790M Mutation

> **NCT03758677** · PHASE2 · UNKNOWN · sponsor: **The First Hospital of Jilin University** · enrollment: 30 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Apatinib

## Key facts

- **NCT ID:** NCT03758677
- **Lead sponsor:** The First Hospital of Jilin University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-08-01
- **Primary completion:** 2020-11-20
- **Final completion:** 2021-11-20
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2020-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03758677

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03758677, "Apatinib Combined With Chemotherapy for NSCLC Patients Without T790M Mutation". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT03758677. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*